PHARMASCROLL
enquiry@pharmascroll.com Mail Us
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
  • Social Media Analytics
  • Research & Consulting Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
PHARMASCROLL
  • Home
  • About Us
    • Mission and Vision
    • Our Team
    • Why PharmaScroll
  • Business Intelligence
  • Social Media Analytics
  • Research & Consulting Services
  • Newsroom
    • Blog
    • Press Release
    • Recent News
      • Neuroscience
        • Migraine
        • Multiple Sclerosis
        • Alzheimer’s
        • Parkinson’s
        • Epilepsy
        • Schizophrenia
        • Depression
        • ADHD
      • Respiratory
        • COPD
        • Asthma
        • Pulmonary Fibrosis
        • Cystic fibrosis
        • Rhinitis
      • Oncology
      • Diabetes
  • Careers
  • Contact Us
enquiry@pharmascroll.com Mail Us
HomeNewsNeuroscienceDepression
  • FDA approves Alembic’s generic drug for Major Depressive Disorder

    • June 12, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Esketamine displays positive Ph 3 trial outcomes for Depression

    • June 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Allergan acquires depression compound from Aptinyx

    • May 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • 33 percent more people suffer from Depression as compared to 2013, new research finds

    • May 11, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Esketamine improves outcomes in Treatment-Resistant Depression patients, new Phase 3 data shows

    • May 8, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • NDA submitted for Brexanolone in Postpartum Depression by Sage Therapeutics

    • April 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
  • Intranasal Esketamine improves Depression symptoms as per latest clinical trial results

    • April 21, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
Newsletter
Recent Posts
  • COPD- How to Manage the disease
  • Prognosis of Epilepsy- Disease definition, Mortality, Relapse risks explained
  • Diagnosing Alzheimer’s disease through symptoms
  • Diet Sources to help prevent Multiple Sclerosis (MS) relapses
  • Symptoms & Treatment For Cystic Fibrosis disease

Contact Us

   enquiry@pharmascroll.com
   +91 96 1837 9037
   First Office, 2nd Floor, Plot No:14,
Behind Dena Bank, Madhapur,
Hyderabad, Telangana 500081
Contact Name: Bhawna Gupta

Recent Tweets

  • List of Social Media Analytics services offered by PharmaScroll https://t.co/XPVSXgQE6Y12 days ago

Recent Posts

  • COPD- How to Manage the disease
  • Prognosis of Epilepsy- Disease definition, Mortality, Relapse risks explained
  • Diagnosing Alzheimer’s disease through symptoms

News Letter

© 2021 Copyright. All rights reserved

Catalyzed by

SPEAK TO AN EXPERT